Arrowhead Pharmaceuticals reported interim signals from RNAi candidates in obesity and announced plans to advance at least one program, ARO‑INHBE, into Phase 2 testing after early cohorts showed fat‑loss signals. Interim data presented alongside Eli Lilly’s Zepbound in combination cohorts showed larger reductions in body weight and visceral and liver fat versus Zepbound alone in patients with obesity and diabetes. The company is positioning RNAi approaches as longer‑acting partners to GLP‑1 therapies and will expand dosing and cohort sizes to confirm durability and safety ahead of Phase 2 starts.